MAF precursor activity has also been lost or reduced after Gc-globulin treatment in some cancer cell lines
1More
35More
Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside - 0 views
-
This appears to result from the deglycosylated ɑ-N-acetylgalactosaminidase (nagalase) secreted from cancerous cells
- ...31 more annotations...
-
Studies have shown that the production of nagalase has a mutual relationship with Gc-MAF level and immunosuppression
-
It has been demonstrated that serum levels of nagalase are good prognosticators of some types of cancer
-
The nagalase level in serum correlates with tumor burden and it has been shown that Gc-MAF therapy progresses, nagalase activity decreases
-
It has been shown that Gc-MAF can inhibit the angiogenesis induced by pro-inflammatory prostaglandin E1
-
The effect of Gc-MAF on chemotaxis or activation of tumoricidal macrophages is likely the main mechanism against angiogenesis.
-
Administration of Gc-MAF stimulates immune-cell progenitors for extensive mitogenesis, activates macrophages and produces antibodies. “This indicates that Gc-MAF is a powerful adjuvant for immunization.”
-
Cancer cell lines do not develop into tumor genes in mouse models after Gc-MAF-primed immunization (29-31) and the effect of Gc-MAF has been approved for macrophage stimulation for angiogenesis, proliferation, migration and metastatic inhibition on tumors induced by MCF-7 human breast cancer cell line
-
The protocol included: "a high dose of second-generation Gc-MAF (0.5 ml) administered twice a week intramuscularly for a total of 21 injections.”
-
Yamamoto et al. showed that the administration of Gc-MAF to 16 patients with prostate cancer led to improvements in all patients without recurrence
-
Inui et al. reported that a 74-year-old man diagnosed with prostate cancer with multiple bone metastases was in complete remission nine months after initiation of GcMAF therapy simultaneously with hyper T/NK cell, high-dose vitamin C and alpha lipoic acid therapy
-
It has also been approved for non-neoplastic diseases such as autism (41), multiple sclerosis (42, 43), chronic fatigue syndrome (CFS) (40), juvenile osteoporosis (44) and systemic lupus erythematous (45).
-
Gc-MAF has been verified for use in colon, thyroid (38), lung (39), liver, thymus (36), pancreatic (40), bladder and ovarian cancer and tongue squamous carcinoma
-
Prostate, breast, colon, liver, stomach, lung (including mesothelioma), kidney, bladder, uterus, ovarian, head/neck and brain cancers, fibrosarcomas and melanomas are the types of cancer tested thus far
-
weekly administration of 100 ng Gc-MAF to cancer at different stages and types showed curative effects at different follow-up times
-
Studies have shown that weekly administration of 100 ng Gc-MAF to cancer patients had curative effects on a variety of cancers
-
Because the half-life of the activated macrophages is approximately one week, it must be administered weekly
-
In vivo weekly intramuscular administration of Gc-MAF (100 ng) for 16-22 weeks was used to treat patients with breast cancer
-
individuals harboring different VDR genotypes had different responses to Gc-MAF and that some genotypes were more responsive than others
-
Administration of Gc-MAF for cancer patients exclusively activates macrophages as an important cell in adaptive immunity
-
Gc-MAF supports humoral immunity by producing, developing and releasing large quantities of antibodies against cancer. Clinical evidence from a human model of breast cancer patients supports this hypothesis
-
It is likely that the best therapeutic responses will be observed when the nutritional and inflammatory aspects are taken together with stimulation of the immune system
-
it should be noted that no harmful side effects of Gc-MAF treatment have been reported, even when it was successfully administered to autistic children
-
The natural activation mechanism of macrophages by Gc-MAF is so natural and it should not have any side effects on humans or animal models even in cell culture
-
Besides the Gc-MAF efficacy on macrophage activity, it can be a potential anti-angiogenic agent (28) and an inhibitor of the migration of cancerous cells in the absence of macrophages (47).
-
Activating or modifying natural killer cells, dendritic cells, DC, CTL, INF and IL-2 have all been recommended for cancer immunotherapy
-
It has been reported that nagalase cannot deglycosylate Gc-MAF as it has specificity for Gc globulin alone
-
inflammation-derived macrophage activation with the participation of B and T lymphocytes is the main mechanism
-
Previous clinical investigations have confirmed the efficacy of Gc-MAF. In addition to activating existing macrophages, Gc-MAF is a potent mitogenic factor that can stimulate the myeloid progenitor cells to increase systemic macrophage cell counts by 40-fold in four days
1More
shared by Nathan Goodyear on 29 Jun 17
- No Cached
Vitamin D and inflammation: Dermato-Endocrinology: Vol 6, No 1 - 0 views
www.tandfonline.com/...19381980.2014.983401
vitamin d inflammation disease lupus RA MS inflammatory disease
![](/images/link.gif)
13More
shared by Nathan Goodyear on 04 Apr 18
- No Cached
Low-dose Interleukin-2 in the Treatment of Autoimmune Disease | touchONCOLOGY - 0 views
www.touchoncology.com/...2-treatment-autoimmune-disease
cancer autoimmune disease Tregs Treg cells Treg immune system disease IL-2
![](/images/link.gif)
Amol kashikar liked it
-
Type 1 diabetes (T1D), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD) account for the majority of the patients with autoimmune diseases
- ...9 more annotations...
-
Autoimmune diseases are characterized by a breakdown of mechanisms that allow the immune system to distinguish between self and nonself and maintain immunologic self-tolerance
-
Several subtypes of Tregs exist, the most well studied being CD4+ cells that express high-level CD25 and the transcription factor forkhead box P3 (FOXP3)
-
In clinical studies, decreased levels of circulating CD25+CD4+ T cells have been reported in patients with autoimmune disease
-
These data have led to the hypothesis that augmentation of Tregs may be a useful therapeutic strategy in autoimmune disease
-
Treg augmentation has resulted in clinical improvements in numerous animal models of autoimmune diseases
-
the administration of in vitro expanded CD4+CD25highCD127-Tregs has been found to be safe and may help to preserve β-cell function in children with T1D
-
Great article. Immune dysfunction plays role in autoimmune disease and cancer. Treg cells sit at the center of autoimmunity. This artice highlights the different uses: low dose IL2 therapy to augment Tregs and reduce autoinflammation and high dose IL2 to augment Treg cells in the fight against cancer.